> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# AstraZeneca Sees Positive Results from Imfinzi in Lung Cancer
- URL: https://www.fdaweb.com/astrazeneca-sees-positive-results-from-imfinzi-in-lung-cancer/
- Published: 2017-05-12T12:00:00.000Z
- Updated: 2026-09-14T22:23:16.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5138683

AstraZeneca and MedImmune have announced positive results from their Phase 3 PACIFIC trial, a randomized, double-blinded, placebo-controlled trial of Imfinzi (durvalumab) as sequential treatment in patients with locally-advanced, unresectable (Stage III) non-small cell lung cancer (NSCLC) who had not progressed following standard platinum-based chemotherapy concurrent with radiation therapy. A planned interim analysis concluded that the trial has already met a primary endpoint by showing statistically-significant and clinically-meaningful progression-free survival in patients receiving Imfinzi compared to placebo, the companies say. The results also showed a favorable benefit/risk profile. Additionally, the trial is evaluating overall survival, but that result will be assessed at a later date.

  
AstraZeneca recently received accelerated FDA approval for Imfinzi in previously treated patients with advanced bladder cancer. The therapy is also being tested in the first-line treatment of patients with NSCLC as monotherapy in the MYSTIC and PEARL Phase 3 trials.